Proposal to develop a gastrointestinal (GI) neuropharmacology platform within the Neurogastroenterology Group (NGG)

Lead Research Organisation: Queen Mary, University of London
Department Name: Blizard Institute of Cell and Molecular

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50
 
Description Advisory Board (gastrointestinal) for Takeda Pharmaceuticals
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Advisory Board (gastrointestinal) for Zealand Pharmaceuticals
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description Editor of Section of IUPHAR database defining the motilin receptor
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Membership of advisory committee
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description Wellcome Trust Peer Review College
Geographic Reach National 
Policy Influence Type Membership of a guidance committee
 
Description A new approach to the treatment of gastroparesis and nausea
Amount £50,000 (GBP)
Organisation Bowel & Cancer Research 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2019 
End 07/2020
 
Description AgeUK
Amount £77,250 (GBP)
Organisation Age UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2013 
End 01/2016
 
Description BBSRC
Amount £102,126 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2014 
End 08/2018
 
Description Bowel and Cancer Research
Amount £45,140 (GBP)
Organisation Bowel Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2012 
End 07/2013
 
Description Contract Research
Amount £32,000 (GBP)
Organisation Transpharmation 
Sector Private
Country United Kingdom
Start 01/2013 
End 12/2013
 
Description Exploratory Research
Amount $50,000 (USD)
Organisation Tioga Ltd, Derby 
Sector Private
Country United Kingdom
Start 09/2013 
End 08/2014
 
Description Exploratory Research
Amount £128,789 (GBP)
Organisation Shire Pharmaceuticals 
Sector Private
Country Ireland
Start 07/2011 
End 06/2012
 
Description GlaxoSmithKline
Amount £32,231 (GBP)
Organisation GlaxoSmithKline (GSK) 
Department Academic Discovery Performance Unit
Sector Private
Country Global
Start 02/2012 
End 01/2013
 
Description Research Collaboration
Amount £120,626 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 09/2009 
End 08/2011
 
Description Research Collaboration
Amount £24,000 (GBP)
Organisation RaQualia Pharma Inc. 
Sector Charity/Non Profit
Country Japan
Start 04/2014 
End 10/2014
 
Description Research Collaboration
Amount £712,625 (GBP)
Organisation Takeda Pharmaceutical Company 
Department Takeda Pharmaceutical Company Ltd
Sector Private
Country United Kingdom
Start 12/2018 
End 12/2020
 
Description Research Collaboration
Amount £220,464 (GBP)
Organisation Protexin 
Sector Private
Country United Kingdom
Start 05/2011 
End 04/2013
 
Description Research Collaboration
Amount £720,836 (GBP)
Organisation Takeda Pharmaceutical Company 
Sector Private
Country Japan
Start 12/2014 
End 11/2017
 
Description Research Collaboration
Amount £9,000 (GBP)
Organisation Protexin 
Sector Private
Country United Kingdom
Start 03/2013 
End 07/2013
 
Description Research Grant
Amount £215,667 (GBP)
Organisation The Dunhill Medical Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2015 
End 01/2018
 
Description UEGF Travel Award for PostDoc
Amount £1,000 (GBP)
Organisation United European Gastroenterology 
Sector Charity/Non Profit
Country Austria
Start 09/2011 
End 10/2011
 
Description Zealand Pharmaceuticals
Amount £19,999 (GBP)
Organisation Zealand Pharma 
Sector Private
Country Denmark
Start 12/2017 
End 11/2018
 
Title Human isolated gastrointestinal functions with translational value 
Description We collect human gastrointestinal tissues removed as a normal part of surgery after informed consent. Motor nerve function is assessed by electrically stimulating the nerves & then dissecting out the nerve phenotypes using pharmacological tools. Tissues are usually from patients with cancer, obesity or inflammatory bowel disease. Some of our methods are not novel but are rarely performed in the UK. Other methods (eg use of stomach) are novel. In each region of the gut translational value is assessed by determining the effects of clinical standards, known to affect gastrointestinal function. In this way, we provide a unique facility (within the UK) - the use of human isolated gastrointestinal tissues to measure function and to compare and validate that function by comparison with clinical standards. Other laboratories do not offer the latter, simply undertaking contract research. 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2012 
Provided To Others? Yes  
Impact Our laboratory is attracting considerable interest from industry. Three different contracts for research (apart from GSK) are currently being negotiated. We have joined a human tissue consortium, offering assays for hire. We are one of the rare labs which offer native tissues and not cell biology. We have trained one other UK lab in techniques 
 
Description Anti-emetic activity of erythromycin 
Organisation University of Huddersfield
Department School of Applied Sciences Huddersfield
Country United Kingdom 
Sector Academic/University 
PI Contribution Direction of the research
Collaborator Contribution The collaborator has access to an animal model of vomiting (currently unique within the UK). My contribution was to direct the research which evaluated the dose-dependent pro- and anti-emetic activities of motilin receptor agonists. This is the first time anti-emetic activity has been demonstrated, using low doses of compound. Overall, such data ties in well with our current interests in motilin and other gastrointestinal hormones.
Impact Data has been prepared as a manuscript which will be submitted for publication before end-2010. Additional data (funded directly to Huddersfield by GSK, but under my direction) evaluated a proprietry compound (manuscript: Javid FA, Bulmer DC, Broad J, Aziz Q, Dukes GE, Sanger GJ (2013). Anti-emetic and emetic effects of erythromycin in Suncus murinus: potential role of vagal activation, increased gastric motility and motilin receptors. Eur J Pharmacol, 699, 48-54.)
Start Year 2010
 
Description Evaluation of human gastrointestinal activity of sera from Chagas patients 
Organisation Queen Mary University of London
Department Barts and The London School of Medicine and Dentistry
Country United Kingdom 
Sector Academic/University 
PI Contribution The new human tissue lab enabled, for the first time, blood sera to be tested on human isolated colon, looking for changes in muscle and motor nerve functions, indicative of changes in motility.
Collaborator Contribution Gave access to sera from Chagas' patients
Impact For the first time we have shown an inhibitory activity on the muscle of naive humab colon which is independent of neuronal activity and not carried by the antibodies within the blood sera. Experiments are ongoing to isolate the mechanism of action. Abstracts prepared for submission but not followed through as source of material became unreliable
Start Year 2010
 
Description Evaluation of kappa opioid receptor agonists in human and mouse colon 
Organisation Tioga Pharmaceuticals
Country United States 
Sector Private 
PI Contribution Conducted and designed research
Collaborator Contribution Supplied data to enable proper design + funding
Impact Publication of manuscript
Start Year 2013
 
Description Evaluation of new drug targets for gastrointestinal disease 
Organisation Shire Pharmaceuticals
Country Ireland 
Sector Private 
PI Contribution Recently started. Focus is on the use of human tissues to measure function
Collaborator Contribution Research collaboration
Impact Mostly contract research. One joint manuscript (Broad J, Kung VWS, Boundouki G, Aziz Q, De Maeyer JH, Knowles CH, Sanger GJ (2013). Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility. Br J Pharmacol, 170, 1253-1261)
Start Year 2011
 
Description Exploration of human gastrointestinal functions of motilin 
Organisation GlaxoSmithKline (GSK)
Department Respiratory Centers for Excellence for Drug Discovery CEDD GSK
Country United Kingdom 
Sector Private 
PI Contribution Provision of a new lab to work on human gastrointestinal tissues removed normally at surgery with informed consent. Development of method of measuring motor nerve function in a range of different human isolated gastrointestinal tissues (esophagus, gastric fundus, gastric antrum, terminal ileum, right and left colon) & demonstration (for the first time) of activity in these models by motilin and motilin receptor agonists. Published as abstracts. Development of immunohistochemistry methods for staining motilin receptors in human gastrointestinal tissues. Measurement of effects of alternative ways of stimulating human gastrointestinal motor nerve functions (5-HT4, AChE inhibition). Abstracts published.
Collaborator Contribution Access to restricted compounds
Impact Provision of a new lab to work on human gastrointestinal tissues (focus on function & also immunohistochemistry) removed normally at surgery with informed consent. Data demonstrating the ability of motilin receptor agonists to facilitate cholinergic (& to a lesser extent, nitrergic) function in human isolated gastrointestinal tissues (esophagus, gastric fundus, gastric antrum, but not terminal ileum, right and left colon). Provides useful data for industry + demonstrated translational value of these human models. Published as abstracts. Provision of Regulatory Documents on GSK propietry compounds, to allow filing for clinical trials. Data demonstrating the ability of a 5-HT4 receptor agonist (prucalopride) and a cholinesterase inhibitor (donepezil, used to treat Alzheimer's) to facilitate motor nerve functions (cholinergic and nitrergic (5-HT4 only)) in human isolated colon, thereby demonstrating the translational value of this model. Abstracts published.
Start Year 2009
 
Description Identification of enteric bacteria modulating intestinal functions 
Organisation Protexin
Country United Kingdom 
Sector Private 
PI Contribution Identification of bacteria from human biopsies. Characterisation of the ability of the bacteria to survive ingestion into the gut and be retained for long enough to have activity. About to begin functional testing.
Collaborator Contribution Access to profiled bacteria and knowhow
Impact Bacteria identified and screened. Too early to report final data.
Start Year 2011
 
Description Research into ghrelin 
Organisation University of Melbourne
Country Australia 
Sector Academic/University 
PI Contribution Research Fellow worked in collaborator laboratory for a short while
Collaborator Contribution Provided intellectual input and laboratory facilities
Impact One peer reviewed publication (original data) One peer-reviewed review One invitation to write a book chapter (completed)
Start Year 2015
 
Description Blog 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Blog

Influence policy
Year(s) Of Engagement Activity 2013
URL http://£HIS: Replacing animals in research (video coinciding with release of Home Office animal use ...
 
Description Blog 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Blog to members of the public

One blog led to another
Year(s) Of Engagement Activity 2013
URL http://£Cut down on animal testing by building a human tissue lab. Published on The Conversation: ht...
 
Description Blog 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Blog

One blog led to another
Year(s) Of Engagement Activity 2013
URL http://£Why not use human material to study human biology and diseases? NC3Rs blog: http://blog.nc3...